mRNA Vaccines Market Intelligence: Size, Share and Growth Outlook Through 2035

Market Overview

Size, share, and commercial baseline

• Brevintel analysis values the mRNA vaccines market at USD 6.2 billion in 2025 ($6.2B), with growth from USD 5.6 billion in 2026 to USD 7.2 billion in 2035 ($7.2B) at a 2.8% CAGR during 2026-2035.
• The commercial baseline reset after revenue fell from USD 56.2 billion in 2022 to USD 6.2 billion in 2025, shifting demand from emergency-volume COVID-19 procurement toward a smaller seasonal respiratory-vaccine business.
• Pfizer led with over 70% market share in 2025, while BioNtech, Moderna, and Pfizer—listed as the top players—collectively held a 100% share.
• North America represented 45.3% of global revenue in 2025, even as U.S. revenue declined from USD 23.9 billion in 2022 to USD 2.6 billion in 2025.
• Europe generated USD 2.0 billion in 2025, and Asia Pacific is projected to record the highest regional CAGR, at 3.5%, through 2035.
• The market is assessed globally for 2026-2035, with 2025 as the base year, covering product, application, patient age group, and end-use segments across North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
• Brevintel analysis treats the modest 2.8% CAGR as a transition away from pandemic purchasing rather than a loss of relevance for the underlying mRNA platform.
• Competitive coverage centers on Pfizer, BioNTech, and Moderna, with pipeline developers discussed where they affect dose economics, delivery routes, or regional supply.

Diversification beyond COVID-19

• Diversification has begun from a narrow base: Moderna's mRESVIA became the first FDA-approved mRNA vaccine for respiratory syncytial virus prevention in May 2024.
• The U.S. mRESVIA indication was expanded in June 2025 to adults aged 18 through 59 at increased risk of RSV-associated lower respiratory tract disease, after the original authorization for adults aged 60 years and older in 2024.
• Japan authorized KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine, showing that next-generation RNA architectures can enter commercial use outside conventional nucleoside-modified mRNA.
• RSV is projected to grow at an 8.4% CAGR, and mRESVIA's expanded U.S. label creates a broader adult risk-based population than its original older-adult authorization.
• Commercial success will depend less on the speed of RNA sequence design than on reimbursement, formulary access, seasonal contracting, and differentiation against established RSV vaccine alternatives.
• Moderna's mNEXSPIKE, a lower-dose COVID-19 vaccine, received FDA approval in May 2025 for adults aged 65 years and older and individuals aged 12 through 64 years at high risk of severe COVID-19.
• Oncology programs such as Moderna and Merck's intismeran autogene in late-stage melanoma remain longer-cycle options and should not be equated with commercial authorization.
• Revenue remains heavily tied to one pathogen and a limited set of suppliers, which is why non-COVID products must still prove durable purchasing and clinical-use patterns.

Market Dynamics

Platform speed, infrastructure, and public preparedness

• mRNA development retains a practical speed advantage when antigen sequences change frequently, because developers can alter the encoded sequence while retaining much of the established LNP delivery, analytical, and manufacturing framework.
• Pfizer and BioNTech's FDA approval for an LP.8.1-adapted Comirnaty formulation in August 2025 demonstrated that strain adaptation remains commercially viable within a seasonal vaccination model.
• FDA approved the supplemental biologics license application for the LP.8.1-adapted Comirnaty formulation on August 27, 2025, for adults aged 65 years and older and individuals aged 5 through 64 years with at least one condition that increases severe-COVID-19 risk.
• Pandemic deployment established specialized RNA synthesis, LNP formulation, fill-finish, pharmacovigilance, and temperature-controlled distribution capabilities at global scale.
• Those assets lower the incremental operational burden of moving into adjacent respiratory indications, although they do not eliminate indication-specific efficacy evidence, clinical contracting, and reimbursement decisions.
• In January 2025, HHS announced USD 590 million for Moderna's mRNA-based pandemic influenza vaccine development program.
• The WHO mRNA Technology Transfer Programme has supported capability development among partner manufacturers in low- and middle-income countries, which could broaden future regional supply options.
• LNP performance affects dose requirements, tolerability, tissue distribution, stability, and manufacturability; advances in ionizable lipids may improve delivery but can also extend chemistry, manufacturing, and controls work.
• RSV prevention provides the clearest near-term commercial test of mRNA diversification after mRESVIA received FDA approval for adults aged 60 years and older in 2024, then gained an expanded high-risk adult indication in 2025.

Manufacturing economics, uptake, and funding constraints

• mRNA vaccine production requires specialized inputs, including plasmid DNA templates, modified nucleotides, enzymes, capping reagents, and lipid components, plus aseptic manufacturing, LNP processing, and cold-chain distribution.
• A process-cost model estimated that establishing capacity for 100 million annual mRNA vaccine doses required USD 127.1 million to USD 270 million in start-up investment.
• Distribution conditions remain particularly important in lower-resource health systems, where cold-chain equipment, dependable electricity, and transportation capacity influence waste and delivered-dose cost.
• Evidence from the Democratic Republic of the Congo identified material cold-chain constraints across surveyed facilities, illustrating why manufacturing access alone does not ensure routine deployment.
• mRESVIA generated USD 25 million in 2024, its first partial commercial year, compared with a global market of USD 8.5 billion, showing that non-COVID products have not yet offset falling COVID-19 sales.
• During the 2024-2025 season, median COVID-19 vaccination coverage among adults aged 60 years and older was 8.7% across reporting EU/EEA countries, and U.S. pediatric coverage remained low.
• In August 2025, HHS announced that it would wind down 22 BARDA mRNA vaccine development investments valued at nearly USD 500 million, adding uncertainty to the U.S. public funding environment.
• Brevintel analysis indicates that the main constraint is not scientific feasibility; it is the mismatch between a flexible development platform and a commercial base still dominated by declining COVID-19 demand.
• The -1.5% impact assigned to manufacturing and cold-chain costs matters most where government tenders, infrastructure limitations, or low-volume seasonal demand prevent fixed costs from being efficiently absorbed.
• Novel lipid excipients can require data packages approaching the level expected for active pharmaceutical ingredients, particularly where the excipient materially affects biodistribution or safety.

Segmentation Analysis

Product

• Comirnaty remains the dominant product, holding approximately 70% of global mRNA vaccine revenue in 2025 and projected to reach USD 4.9 billion by 2035 at a 2.6% CAGR.
• Its position depends on annual strain updates, broad distribution reach, and continued use among populations at higher risk of severe COVID-19; the 2025 LP.8.1 formulation approval shows the operational importance of seasonal regulatory responsiveness.
• Spikevax generated USD 1.4 billion in 2025 and is projected to expand at a 3.1% CAGR through 2035, reflecting a lower revenue base after the contraction of pandemic-era purchasing.
• Moderna's larger strategic distinction is its broader approved mRNA respiratory portfolio, which includes Spikevax, mRESVIA, and mNEXSPIKE.
• mRESVIA is the principal non-COVID commercial growth asset, approved in the United States and Europe, with the U.S. label covering adults aged 18 through 59 at increased risk and older adults.
• Other products include mNEXSPIKE, Moderna's lower-dose COVID-19 vaccine approved by FDA in May 2025, and KOSTAIVE, the self-amplifying mRNA product authorized in Japan.
• KOSTAIVE is strategically significant because self-amplifying designs may achieve antigen expression at lower mRNA doses, although its commercial footprint remains geographically limited.
• Pfizer's 2025 Comirnaty revenue of USD 4.367 billion confirms the product's continued role in seasonal respiratory vaccination.

Application and patient age group

• COVID-19 prevention accounted for 99.9% of 2025 market revenue; its share is expected to decline as RSV and prospective pipeline applications grow, even if absolute COVID-19 revenue stabilizes among older adults and risk-based populations.
• RSV prevention is projected to achieve an 8.4% CAGR through 2035, resting on mRESVIA's ability to secure access in adult clinical care where competing RSV vaccines are already established.
• The pediatric segment generated USD 2.0 billion in 2025 and is expected to grow at a 2.5% CAGR, constrained by lower COVID-19 vaccination uptake among children and the absence of approved pediatric mRNA RSV products.
• Adult revenue is projected to expand at a 3.1% CAGR, supported by risk-based COVID-19 vaccination and the expanded mRESVIA indication for high-risk adults aged 18 through 59.
• The geriatric segment is projected to grow at a 2.7% CAGR, reflecting its established role in COVID-19 and RSV vaccination, alongside relatively mature penetration in higher-income markets.
• Brevintel analysis finds the most consequential imbalance remains the divergence between application growth and age-group demand: RSV offers the fastest application growth at 8.4%, yet pediatric expansion remains constrained.
• Products that extend the platform into adult RSV care may improve revenue resilience sooner than those aimed at broad population COVID-19 booster volumes.
• Regulatory recommendations and annual strain selection will continue to shape seasonal COVID-19 procurement volumes even as the 99.9% application share recedes.

End use

• Government immunization programmes accounted for 63.2% of revenue in 2025 and are projected to generate USD 4.2 billion by 2035.
• This channel remains influential because national recommendations, tender structures, and stockpile policies directly affect order volumes.
• The change in U.S. BARDA policy illustrates that government support can shift from active development funding to narrower seasonal procurement.
• Hospitals and clinics are projected to be the fastest-growing end-use segment, at a 4.4% CAGR, reflecting migration from emergency mass campaigns toward provider-based seasonal administration, particularly for adult RSV prevention.
• Other end users, including academic institutions, NGOs, and vaccination centers, remain relevant mainly to clinical development, public-health delivery, and targeted access programs.
• Brevintel analysis suggests that segment performance will increasingly be determined by channel fit rather than by mRNA technology alone.
• COVID-19 products continue to underpin revenue, but the 4.4% CAGR projected for hospitals and clinics signals a shift toward provider-led, adult respiratory vaccination.
• That transition favors suppliers able to negotiate contracting and reimbursement across fragmented clinical channels rather than relying primarily on centralized emergency procurement.

Regional Outlook

North America and Europe

• North America held 45.3% of global market revenue in 2025, giving the region disproportionate influence even after pandemic-era purchasing faded.
• The United States remains the region's principal market, despite revenue falling from USD 23.9 billion in 2022 to USD 2.6 billion in 2025.
• The decline reflects the end of broad emergency purchasing, lower booster uptake, and the transition to seasonal commercial ordering.
• The August 2025 BARDA wind-down adds uncertainty for early-stage U.S.-funded mRNA development, even as commercial opportunities in COVID-19 and RSV remain.
• Europe generated USD 2.0 billion in 2025.
• The EMA authorized mRESVIA for adults aged 18 years and older in August 2024, creating a broader eligible adult population than the product's original U.S. approval.
• Low COVID-19 coverage among older adults across EU/EEA reporting countries, including 8.7% median coverage among adults aged 60 years and older in the 2024-2025 season, indicates that demand recovery will depend on reimbursement and distinct RSV clinical demand.
• North America's declining U.S. revenue base means that future gains must come from RSV adoption, new respiratory products, and clinical-channel execution rather than emergency-scale COVID-19 orders.

Asia Pacific, Latin America, and Middle East & Africa

• Asia Pacific is projected to grow at a 3.5% CAGR, the highest regional rate through 2035.
• Japan provides a commercial proof point through KOSTAIVE's authorization and distribution, while regional growth also depends on expanding domestic manufacturing capability and regulatory pathways.
• Local clinical evidence requirements in large Asian markets can delay imported-product entry, but they may also support the development of domestic mRNA platforms and regional supply chains.
• Japan's authorization of a self-amplifying mRNA vaccine demonstrates regional willingness to commercialize alternative RNA architectures.
• Latin America is expected to record robust growth from a smaller base, with public immunization programmes, regional procurement mechanisms, and gradual cold-chain improvements influencing adoption more directly than private-market demand.
• The WHO mRNA Technology Transfer Programme may support longer-term localization of manufacturing capability, but local production must still be matched with financing, regulatory capacity, and viable procurement volumes.
• The Middle East and Africa are also expected to grow robustly from a low base; Gulf markets offer comparatively developed healthcare infrastructure, whereas many African markets face material cold-chain and last-mile distribution constraints.
• South Africa's role as the WHO mRNA technology-transfer hub is strategically important for capability building, but infrastructure reliability and sustainable procurement remain decisive for wider commercial deployment.

Competitive Landscape

Authorized-market structure

• The authorized commercial market is concentrated among Pfizer, BioNTech, and Moderna, reflecting barriers in LNP know-how, RNA manufacturing, regulatory documentation, commercial-scale quality systems, and government procurement relationships.
• Pfizer led with over 70% market share in 2025, and BioNtech, Moderna, and Pfizer collectively held a 100% share; competitive narrative also states that Moderna held approximately 70% while Pfizer and BioNTech accounted for the remaining share.
• Pfizer commercializes Comirnaty with BioNTech through a collaboration that includes equal gross-profit sharing in most markets outside China, Hong Kong, Macau, and Taiwan.
• Pfizer's 2025 Comirnaty revenue of USD 4.367 billion and the LP.8.1-adapted formulation approval reinforce its ability to execute strain updates within the U.S. commercial market.
• BioNTech contributes the mRNA technology foundation of the Comirnaty partnership while pursuing oncology diversification, including autogene cevumeran and other development-stage candidates that should be distinguished from existing vaccine revenue.
• Moderna is the only company with three authorized mRNA respiratory products: Spikevax, mRESVIA, and mNEXSPIKE.
• Moderna reported USD 3.2 billion in total 2024 revenue, including USD 3.1 billion from Spikevax and USD 25 million from mRESVIA in its initial partial year.
• Arcturus Therapeutics and Meiji Seika Pharma are commercially relevant through KOSTAIVE in Japan.
• Daiichi Sankyo, Ethris, Sanofi, Providence Therapeutics, Strand Therapeutics, and Orna Therapeutics represent differentiated pipeline approaches spanning oncology, inhaled delivery, self-amplifying RNA, and circular RNA.
• These pipeline companies do not currently alter the concentrated authorized-market structure, but their platform choices could influence future dose economics, delivery routes, and product differentiation.

Recent industry developments

• On August 27, 2025, Pfizer and BioNTech received FDA approval for the LP.8.1-adapted Comirnaty formulation for adults aged 65 years and older and at-risk individuals aged 5 through 64 years.
• On August 5, 2025, HHS announced the wind-down of 22 BARDA mRNA vaccine development investments valued at nearly USD 500 million, including contract terminations, de-scoping of mRNA work, and rejection of certain pre-award solicitations.
• On June 12, 2025, FDA expanded mRESVIA's indication to include adults aged 18 through 59 years at increased risk of RSV-associated lower respiratory tract disease.
• In May 2025, FDA approved Moderna's mNEXSPIKE for adults aged 65 years and older and individuals aged 12 through 64 years with at least one underlying condition that places them at high risk for severe COVID-19.
• RSV's projected 8.4% CAGR will not automatically translate into broad mRNA platform expansion; mRESVIA must compete for reimbursement, formulary placement, and provider adoption in a market already served by protein-based vaccines.
• The U.S. withdrawal of BARDA support from multiple mRNA projects further raises the value of diversified geographic funding, established manufacturing capacity, and commercially credible late-stage programs.
• Brevintel analysis finds the commercial contest will center on seasonal contracting, adult-channel access, and indication expansion rather than on first-generation COVID-19 scale.
• mRESVIA received FDA approval for adults aged 60 years and older in 2024, then gained the expanded high-risk adult indication in 2025, making RSV the principal approved non-COVID application.

Integrated producers

• Pfizer
• BioNTech
• Moderna

Specialty suppliers

• Arcturus Therapeutics
• Meiji Seika Pharma
• Daiichi Sankyo
• Ethris
• Sanofi
• Providence Therapeutics
• Strand Therapeutics
• Orna Therapeutics
• Merck